Search results for "Solitary Fibrous Tumors"

showing 7 items of 7 documents

Solitary Fibrous Tumor of the Vulva: Report of 2 Cases, Including a De Novo Dedifferentiated Solitary Fibrous Tumor Diagnosed After Molecular Demonst…

2018

Solitary fibrous tumor (SFT) is a neoplasm of fibroblastic lineage that has been documented in almost every anatomic location. Vulval SFT is very rare with only 10 cases reported to date. We present 2 additional SFTs located in the vulva, in adult women of 59 and 25 yr of age. The first showed a classic morphology and immunophenotype with uniform and strong STAT6 nuclear expression. The other one was a spindle-cell de novo dedifferentiated SFT with heterogeneous nuclear and cytoplasmic STAT6 staining, which could only be correctly diagnosed after molecular analysis with demonstration of a NAB2-STAT6 gene fusion. This genetic aberration is considered to represent the major pathogenic driver …

0301 basic medicineAdultPathologymedicine.medical_specialtySolitary fibrous tumorLineage (genetic)Oncogene Proteins FusionBiologyPathology and Forensic MedicineVulvaVulva03 medical and health sciences0302 clinical medicineImmunophenotypingmedicineNeoplasmHumansOncogene FusionDedifferentiated Solitary Fibrous TumorVulvar NeoplasmsObstetrics and GynecologyMiddle Agedmedicine.diseaseRepressor Proteins030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisSolitary Fibrous TumorsOncogene FusionFemaleDifferential diagnosisSTAT6 Transcription FactorInternational journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
researchProduct

Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial

2020

[Background] Solitary fibrous tumour is an ultra-rare sarcoma, which encompasses different clinicopathological subgroups. The dedifferentiated subgroup shows an aggressive course with resistance to pazopanib, whereas in the malignant subgroup, pazopanib shows higher activity than in previous studies with chemotherapy. We designed a trial to test pazopanib activity in two different cohorts of solitary fibrous tumour: the malignant-dedifferentiated cohort, which was previously published, and the typical cohort, which is presented here.

0301 basic medicineMalemedicine.medical_specialtyIndazolesPazopanib03 medical and health sciences0302 clinical medicineInternal medicinemedicineClinical endpointHumansProspective StudiesNeoplasm MetastasisProspective cohort studySurvival rateProtein Kinase InhibitorsResponse Evaluation Criteria in Solid TumorsAgedSulfonamidesPerformance statusbusiness.industryMiddle Agedmedicine.diseasePrognosisClinical trialSurvival Rate030104 developmental biologyPyrimidinesOncologyResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisSolitary Fibrous TumorsFemalebusinessProgressive diseasemedicine.drugFollow-Up Studies
researchProduct

Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highli…

2017

Abstract Background Preclinical models that mimic pathological and molecular features of solitary fibrous tumour (SFT) represent an important tool to select effective regimes and novel compounds to be tested in the clinic. This study was aimed at developing two preclinical models of SFT, assessing their predictive value in the clinic and selecting potential novel effective treatments. Material and methods Two dedifferentiated-SFT (D-SFT) models obtained from patients' biopsies were grown in immunodeficient mice. The antitumour activity on these models of doxorubicin, dacarbazine (DTIC), ifosfamide (monotherapy or combination), trabectedin and eribulin was tested. Twelve SFT patients were tr…

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_treatmentSolitary fibrous tumourSoft Tissue NeoplasmsDioxoleMice SCIDPharmacologyAnthracyclineMetastasichemistry.chemical_compound0302 clinical medicineSolitary Fibrous TumorRetrospective StudieTetrahydroisoquinolinesAntineoplastic Combined Chemotherapy ProtocolsTetrahydroisoquinolineMeningeal NeoplasmsMeningeal NeoplasmPleural NeoplasmTrabectedinIfosfamideKidney NeoplasmSarcomaKetonesMiddle AgedMice modelKetoneKidney NeoplasmsDacarbazineSurvival RateOncologyResponse Evaluation Criteria in Solid TumorsSolitary Fibrous Tumors030220 oncology & carcinogenesisFemalemedicine.drugEribulinHumanAdultmedicine.medical_specialtyXenograft Model Antitumor AssayAnthracyclinePleural NeoplasmsDacarbazineBlotting WesternResponse Evaluation Criteria in Solid TumorDioxolesDisease-Free Survival03 medical and health sciencesInternal medicinemedicineAnimalsHumansChemotherapyFuranDoxorubicinRetroperitoneal NeoplasmsEribulinIfosfamideSoft Tissue NeoplasmCerebellar NeoplasmsFuransResponse Evaluation Criteria in Solid TumorsRetrospective StudiesAgedChemotherapyAntineoplastic Combined Chemotherapy ProtocolRetroperitoneal Neoplasmbusiness.industryAnimalXenograftCerebellar NeoplasmXenograft Model Antitumor AssaysTreatment030104 developmental biologychemistryDoxorubicinbusinessTrabectedin
researchProduct

Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour

2014

Abstract Background To explore the activity of pazopanib in solitary fibrous tumour (SFT). Patients and methods In a preclinical study, we compared the activity of pazopanib, sorafenib, sunitinib, regorafenib, axitinib and bevacizumab in a dedifferentiated-SFT (DSFT) xenotransplanted into Severe Combined Immunodeficiency (SCID) mice. Antiangiogenics were administered at their reported optimal doses when mean tumour volume (TV) was 80 mm3. Drug activity was assessed as TV inhibition percentage (TVI%). From May 2012, six consecutive patients with advanced SFT received pazopanib, on a national name-based programme. In one case sunitinib was administered after pazopanib failure. Results In the …

Chemotherapy; Pazopanib; Sarcoma; Solitary fibrous tumour; Sunitinib; Tyrosine kinase; Administration Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies Monoclonal Humanized; Antineoplastic Agents; Bevacizumab; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Male; Mice SCID; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptor Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sulfonamides; Transplantation Heterologous; Vascular Endothelial Growth Factor Receptor-2; Cancer Research; Oncology; Medicine (all)OncologyMaleCancer ResearchIndolesAxitinibPyridinesPyridinemedicine.medical_treatmentSolitary fibrous tumourAdministration OralAngiogenesis InhibitorsMice SCIDPharmacologyPyrroleAntineoplastic Agentchemistry.chemical_compoundMiceSolitary Fibrous TumorChemotherapy; Pazopanib; Sarcoma; Solitary fibrous tumour; Sunitinib; Tyrosine kinase; Cancer Research; Oncology; Medicine (all)Transplantation HeterologouMonoclonalSunitinibHumanizedSulfonamidesHeterologousSunitinibMedicine (all)ImidazolesSarcomaMiddle AgedSorafenibPlatelet-Derived Growth Factor betaAxitinibBevacizumabOncologySolitary Fibrous TumorsAdministrationAngiogenesis InhibitorHumanmedicine.drugReceptorPhenylurea CompoundSorafenibOralAdultNiacinamidemedicine.medical_specialtyIndazolesBevacizumabMAP Kinase Signaling SystemTransplantation HeterologousAntineoplastic AgentsSulfonamideAntibodies Monoclonal HumanizedSCIDAntibodiesReceptor Platelet-Derived Growth Factor betaPazopanibInternal medicineRegorafenibmedicineAnimalsHumansChemotherapyPyrrolesImidazoleTyrosine kinaseAgedChemotherapyTransplantationAnimalbusiness.industryPhenylurea CompoundsPazopanibmedicine.diseaseChemotherapy; Pazopanib; Sarcoma; Solitary fibrous tumour; Sunitinib; Tyrosine kinase; Administration Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies Monoclonal Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Male; Mice SCID; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptor Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sorafenib; Sulfonamides; Sunitinib; Transplantation Heterologous; Vascular Endothelial Growth Factor Receptor-2Vascular Endothelial Growth Factor Receptor-2IndazolePyrimidinesPyrimidinechemistryIndolebusinessProgressive diseaseNeoplasm Transplantation
researchProduct

Solitary Fibrous Tumor: Integration of Clinical, Morphologic, Immunohistochemical and Molecular Findings in Risk Stratification and Classification Ma…

2021

Although solitary fibrous tumors (SFTs) have an unpredictable evolution, some specific clinicopathologic factors have been associated with the final outcome. We retrieved clinical, pathological and molecular data of 97 patients with a histological diagnosis of SFT and Signal transducer and activator of transcription 6 (STAT6) positivity. We retrospectively studied the pathological factors predictive of recurrence/metastasis and compared them with the clinical outcome. A wide immunohistochemical study and molecular analysis to detect NAB2/STAT6 gene fusion, tumor protein-53 (TP53) and/or (telomerase reverse transcriptase) TERT promotor mutation were performed. The risk of metastasis was calc…

MalePathologymedicine.medical_specialtySolitary fibrous tumorQH301-705.5CD99CD34APAF-1Risk AssessmentArticleCatalysisMetastasisInorganic ChemistryBiomarkers TumormedicineHumanssolitary fibrous tumorTelomerase reverse transcriptaseBiology (General)risk stratification systemsPhysical and Theoretical ChemistryQD1-999Molecular BiologyPathological<i>p53</i> mutationSpectroscopyRetrospective StudiesSTAT6<i>HTER</i> mutationbusiness.industryOrganic ChemistrySoft tissueGeneral MedicineMiddle AgedPrognosismedicine.diseaseCombined Modality TherapyImmunohistochemistryp53 mutationComputer Science ApplicationsChemistryHTER mutationSolitary Fibrous TumorsImmunohistochemistryFemaleNeoplasm Recurrence LocalbusinessFollow-Up StudiesInternational Journal of Molecular Sciences
researchProduct

Solitary fibrous tumor surrounding the carotid sheath.

2009

Solitary fibrous tumors (SFTs) are rare spindle cell neoplasms that are mostly found arising from the pleura. Although SFTs recently have been reported in other regions, they are rare in the head and neck and have often been misdiagnosed due to their rarity. SFTs are benign in most cases. Clinically, SFTs usually manifest as wellcircumscribed, slow-growing, smooth and painless masses. Symptoms are often minimal, although they may include sore throat, difficulty in swallowing, change of voice or trismus. CT-Scan and MRI are the most sensitive imaging procedures used. The treatment of choice is complete surgical excision of the lesion. Because recurrences have been noted up to 30 years after …

Malemedicine.medical_specialtySolitary fibrous tumorTrismusLesionYoung AdultSwallowingmedicineParapharyngeal spaceSore throatHumansGeneral DentistryPathologicalbusiness.industryCarotid sheathmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Surgerymedicine.anatomical_structureCarotid ArteriesOtorhinolaryngologyHead and Neck NeoplasmsSolitary Fibrous TumorsUNESCO::CIENCIAS MÉDICASSurgerymedicine.symptombusinessMedicina oral, patologia oral y cirugia bucal
researchProduct

Controversial issues in soft tissue solitary fibrous tumors: A pathological and molecular review

2019

The clinical evolution of solitary fibrous tumor (SFT) remains unclear. Although various clinical, morphological and molecular criteria may indicate increased risk of malignancy, some SFT can still progress despite having a clearly benign appearance. Various risk stratification systems have been proposed, but unfortunately they are not sufficient to precisely determine the malignant potential. In this review, we discuss current knowledge on SFT, focusing on the following controversial issues: (i) the diverse morphologic spectrum: 'the great simulator;' (ii) malignant transformation or dedifferentiation; (iii) current risk stratification systems; and (iv) molecular factors associated with cl…

Risk0301 basic medicinePathologymedicine.medical_specialtySolitary fibrous tumorMalignancyPathology and Forensic MedicineMalignant transformationDiagnosis Differential03 medical and health sciences0302 clinical medicinemedicineHumansPathologicalbusiness.industrySoft tissueGeneral MedicineCell DedifferentiationPrognosismedicine.diseaseImmunohistochemistryCell Transformation Neoplastic030104 developmental biologyIncreased riskSolitary Fibrous Tumors030220 oncology & carcinogenesisRisk stratificationbusinessPathology International
researchProduct